Clarifying the categorization of anaphylaxis as an adverse event during oral immunotherapy
- PMID: 35491265
- DOI: 10.1016/j.jaci.2022.02.032
Clarifying the categorization of anaphylaxis as an adverse event during oral immunotherapy
Comment in
-
Reply.J Allergy Clin Immunol. 2022 Jul;150(1):230-232. doi: 10.1016/j.jaci.2022.03.027. Epub 2022 Apr 28. J Allergy Clin Immunol. 2022. PMID: 35491264 No abstract available.
Comment on
-
Safety of peanut (Arachis hypogaea) allergen powder-dnfp in children and teenagers with peanut allergy: Pooled summary of phase 3 and extension trials.J Allergy Clin Immunol. 2022 Jun;149(6):2043-2052.e9. doi: 10.1016/j.jaci.2021.12.780. Epub 2021 Dec 29. J Allergy Clin Immunol. 2022. PMID: 34971646 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical